SIENI Holdings
SIENI Holdings is a pioneering biotech company focused on developing localized therapies for the treatment of musculoskeletal conditions, including inflammation, infection, pain, and the prevention of post-surgical complications. Their mission is to enable faster healing and safer recovery by minimizing systemic drug exposure through their innovative AEGEAL platform, which delivers FDA-approved drugs directly to the site of injury or surgery. SIENI's vision is to provide versatile, precise, and bioresponsive solutions adaptable across orthopedic, trauma, burn, and veterinary applications, addressing a significant global health burden and market opportunity.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Injectable gel drug-delivery platform
An injectable hydrogel platform developed with validated nanotechnology to enable localized, controlled and sustained delivery of approved therapeutics to musculoskeletal and trauma sites; designed for use in surgical and non-surgical settings and adaptable for human and veterinary applications.
Injectable gel drug-delivery platform
An injectable hydrogel platform developed with validated nanotechnology to enable localized, controlled and sustained delivery of approved therapeutics to musculoskeletal and trauma sites; designed for use in surgical and non-surgical settings and adaptable for human and veterinary applications.
Expertise Areas
- Localized drug delivery
- Biomaterials and hydrogel formulation
- Nanotechnology-enabled therapeutic delivery
- Musculoskeletal therapeutic development
Key Technologies
- Injectable hydrogels
- Nanoparticle-assisted delivery
- Controlled-release formulations
- Bioresponsive materials
Key People
Fractional CCO/CBO
Fractional CCO/CBO
News & Updates
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!